McFarlane Isabel M, Ozeri David J, Pathiparampil Joshy, Sanchez Randolph, Levinson Justin, Barrett-Campbell Odeth, Saladini-Aponte Carla, Boisette Beatrix, Salifu Moro
Department of Medicine, Division of Rheumatology and Nephrology, State University of New York, Downstate Medical Center/Health and Hospitals Kings County Brooklyn, USA.
Rheumatology (Sunnyvale). 2017 Jun;7(2). doi: 10.4172/2329-8731.1000218. Epub 2017 Apr 28.
Rheumatoid arthritis (RA) has been rarely reported in association with sickle cell disease (SCD). Our study aimed to estimate the prevalence of RA in SCD population and to describe the clinical characteristics of RA associated with SCD.
Retrospective chart review of SCD and RA patients followed at 2 large urban hospitals. Seven RA/SCD patients were identified and compared to age and sex matched cohort of SCD only and of RA only group. All patients were Black.
There were 739 SCD cases, seven (0.94%) met ACR criteria for RA (SCD-RA), 411 cases were RA only group. Mean age was significantly higher in SCD-RA compared to the entire population of SCD and RA (41.7 ± 3.9 (± SEM) . 33.26 ± 0.47, . 61.39 ± 0.79, p<0.01). SCD-RA patients had lower hemoglobin (g/dl) when compared to the age and sex matched SCD or RA only patients (7.4 ± 0.49 8.3 ± 0.60 . 11 ± 0.59, p <0.01) respectively. There were no significant differences in laboratory and treatment approach between SCD-RA and RA only groups, except for the radiographic evidence of periarticular osteopenia and greater difficulty in the activities of daily living (ADL) among SCD-RA cohort, compared to the age and sex matched RA cohort (p=0.01).
In contrast to older reports, the prevalence of RA among SCD patients in our study (0.94%) was similar to that reported in the general population (0.5-1%) and was to be associated with difficulty in ADL and periarticular osteopenia. Since RA manifests at an older age, our reported prevalence is likely explainable by improved survival of SCD patients due to enhanced medical care and the advent of hydroxyurea as a major therapeutic breakthrough for SCD.
类风湿性关节炎(RA)与镰状细胞病(SCD)相关的报道很少。我们的研究旨在估计SCD人群中RA的患病率,并描述与SCD相关的RA的临床特征。
对两家大型城市医院随访的SCD和RA患者进行回顾性病历审查。确定了7例RA/SCD患者,并与年龄和性别匹配的单纯SCD队列和单纯RA队列进行比较。所有患者均为黑人。
共有739例SCD病例,其中7例(0.94%)符合RA的ACR标准(SCD-RA),411例为单纯RA组。与整个SCD和RA人群相比,SCD-RA的平均年龄显著更高(41.7±3.9(±标准误)。33.26±0.47,。61.39±0.79,p<0.01)。与年龄和性别匹配的单纯SCD或单纯RA患者相比,SCD-RA患者的血红蛋白(g/dl)更低(分别为7.4±0.49 8.3±0.60。11±0.59,p<0.01)。SCD-RA组和单纯RA组在实验室检查和治疗方法上没有显著差异,除了与年龄和性别匹配的RA队列相比,SCD-RA队列中关节周围骨质减少的影像学证据以及日常生活活动(ADL)困难更大(p=0.01)。
与既往报道不同,我们研究中SCD患者中RA的患病率(0.94%)与普通人群报道的患病率(0.5-1%)相似,且与ADL困难和关节周围骨质减少有关。由于RA在老年时出现,我们报道的患病率可能可以通过SCD患者因医疗护理改善和羟基脲作为SCD的主要治疗突破而提高生存率来解释。